Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have entered into an exclusive license agreement for HRS-5346 ...

Li, president, Merck Research Laboratories. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio ...

Merck&Co., Inc., an American multinational biopharmaceutical company, has entered into an agreement to acquire the rights to the experimental drug HRS-5346, developed by China's Jiangsu Hengrui ...

(RTTNews) - Merck & Co., Inc. (MRK), a healthcare company, on Tuesday announced signing of an exclusive license agreement for HRS-5346 with Jiangsu Hengrui Pharmaceuticals Co., Ltd. HRS-5346 is an ...

Under the agreement, Merck will have the exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. The transaction is expected to close in ...

Merck gains global rights to HRS-5346, an oral Lp(a) inhibitor, excluding Greater China, under a deal with Hengrui Pharma. Hengrui Pharma gets $200M upfront, up to $1.77B in milestones ...

Under the latest deal, Merck gets exclusive rights to develop, manufacture and sell Jiangsu Hengrui Pharmaceuticals’ experimental oral heart disease drug, HRS-5346. Hengrui Pharma will receive an ...

Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the latest in a series of deals U.S. drugmakers have recently signed with ...

In a deal that could reach nearly $2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. has licensed a small molecule for treating cardiovascular disease to Merck & Co. Inc., dropping the China-based ...

The exclusive partnership centers on HRS-5346, an oral inhibitor of lipoprotein(a), or Lp(a), a key risk factor for causing cardiovascular diseases. Per the deal terms, Merck (NYSE:MRK ...